

Research Ethics Committee Reference Number	Full Name of Trial	Date of Receipt of Valid Research Application	Date of First Patient Recruited	Reasons for not achieving the 70 day target from receipt of valid research application to 1st patient recruited										Comments	Reasons for delay correspond to:		
				A - Permissions delayed/denied	B - Suspended by sponsor	C - Closed by sponsor	D - Sponsor Delays	E - Staff availability issues	F - No patients seen	G - No patients consented	H - Contracting delays	I - Rare diseases	J - Other				
13/LO/1595	Cognitive behavioural therapy vs standardised medical care for adults with Dissociative non-Epileptic Seizures: A multi-centre randomised controlled trial (CODES).	17/10/2014	12/11/2014													70 day target met	Neither
14/LO/1381	Reformulated naltrexavi q.d. (1200 mg) versus naltrexavi b.i.d. (400 mg) in ARF-nalve pts (ONCE)	22/10/2014	13/11/2014													70 day target met. Recruitment target of 5 met.	Neither
14/ES/0072	How can we optimise inhaled beta2 agonist dose as 'reliever' medicine for wheezy pre-school children.	15/10/2014	13/03/2015									Y				As at end of September there were >10 screened, but most ineligible or declined. First patient recruited 13.3.15	Neither
13/LO/0699	Evaluating the effects of novel GLP-1 analogue, lixisenatide, in patients with Alzheimer's disease (ELAD study)	30/10/2014	24/03/2015						Y		Y					Difficult to find patients with early AD. PI on extended leave Dec14/Jan15	NHS Provider
13/YH/0147	A randomized, Open Label, Multi-Centre, Controlled Study to Assess Safety and efficacy of ELAD in subjects with Acute Alcoholic Hepatitis (AAH) Who have failed Steroid Therapy (incorporating VT-210E as a follow up registry)	12/11/2014	NA							Y						Difficult recruitment criteria. Patients not eligible. Study closed to recruitment 21/8/15	Neither
14/LO/1513	A Randomized, Open Label, Phase 4 Study Evaluating the Renal Effect of Entegavir/Cobicistat/Emtricitabine/Tenofovir DF or other Tenofovir DF-containing Regimens (Ritonavir-boosted Atazanavir plus Emtricitabine/Tenofovir DF or Efavirenz, Emtricitabine/Tenofovir DF) compared to Ritonavir boosted Atazanavir plus Abacavir/Lamivudine in Antiretroviral Treatment-naïve HIV-1 Infected Adults with eGFR 270 ml/min	23/10/2014	05/02/2015				Y					Y				Memo dated 20/11/14 refers to sponsor delay due to drug supply. First patient screened 21/12/15 but failed screen on viral load. FPR 5.2.15.	Sponsor
14/WM/0083	A Phase III Trial of Surgery versus Active Monitoring for Low Risk Ductal Carcinoma in Situ (DCIS) (LORIS)	01/10/2014	09/09/2015	Y			Y					Y	Y			Site activation delayed post-SIV as no contract was in place. Once this was resolved, the Sponsor issued an amendment, so recruitment could not commence until the amendment was processed and given all relevant approvals. Amendment approved 6th Jan 2015. First patient recruited 9/8/15	Both
11/NW/0548	RIALO: A Randomised Investigation of Alternative Olanatumab-containing regimens in less fit patients with CLL	13/10/2014	09/09/2015									Y				First patient recruited 9/9/15. Prior to this, every effort was made to recruit to this study. 7 patients screened (not eligible), then the study was put on hold due to drug supply issues. These issues arose after the FPR date, so did not affect the target not being achieved.	Neither
12/LO/1109	A Prospective Randomised Phase III Study of Observation Versus Screening MRI And Pre-Empire Treatment in Castrate Resistant Prostate Cancer Patients With Spinal Metastasis	17/10/2014	09/12/2014													70 day target met	Neither
13/SC/0111	FOCUS4 - Molecular selection of therapy in colorectal cancer: a molecularly stratified randomised controlled trials programme	24/10/2014	NA	Y			Y									Delays with sending/completing study documentation meant we were unable to commence recruitment until Jan 2015. Screened many but not recruited. Reduced target figures and changed method of screening but still no eligible patients	Both
14/LO/0298	A multicenter, Single Arm Study of Enzalutamide in Patients with Progressive Metastatic Castration-Resistant Prostate Cancer Previously Treated With Abiraterone Acetate.	30/10/2014	25/11/2014													70 day target met.	Neither
14/LO/1052	A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)	18/11/2014	06/01/2015													70 day target met	Neither
14/EM/1070	A Phase III, Randomized, Double-blind, Placebo-Controlled, Multicenter Clinical Study Evaluating the Safety and Efficacy of Licabtag as a Treatment for Angiotensin-Converting Enzyme Inhibitor (ACE-I)-Induced Angioedema in Adults	22/12/2014	10/03/2015										Y			Rare disease type, but only missed 70 day target by 8 days.	Neither
14/YH/0088	Phase I study of KHK2923 in Patients with Acute Myeloid Leukaemia or Myelodysplastic Syndrome	17/12/2014	29/04/2015				Y									The principle reason for lack of recruitment is study design. It is a cohort study, and patient slots have to be reserved for identified patients before consent and screening can occur. We have identified 3 potential patients for this study, the first in January 2015, but due to competing sites and safety issues we were not given a cohort slot until April 2015.	Sponsor
13/YH/0394	Multi-centre Randomised Controlled Trial of Angiotensin Converting Enzyme Inhibitor (ACE) /Angiotensin Receptor Blocker (ARB) withdrawal in advance renal disease: The STOP-ACE Trial	14/10/2014	14/11/2014													70 day target met	Neither
14/YH/0086	RESPOND: Reproductive Lotus Valve System-Post Market Evaluation of Real World Clinical Outcomes	06/10/2014	22/10/2014													70 day target met	Neither
14/SC/1161	Prospective, single-arm, Multi-centre, observational registry to Further Validate Safety and Efficacy of the Ultmaster DES system in unselected patients representing everyday clinical practice	18/12/2014	22/12/2014													70 day target met	Neither
14/WM/0013	A Randomized, Double blind, Placebo-Controlled, 2-Part Study of Orally Administered ALS-008176 to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Dosing and Multiple Ascending Dosing in Infants Hospitalized with Respiratory Syncytial Virus (RSV) Infection.	19/12/2014	NA				Y				Y					IMP not received until 7/1/15 (sponsor delay). No eligible patients as at 30/9/15 - all meeting inclusion criteria	Sponsor
13/LO/1891	More Response on Cardiac Resynchronization Therapy (CRT) with MultiPoint Pacing (MPP)	04/11/2014	07/01/2015													70 day target met	Neither
13/LO/0145	A multicentre phase III randomised controlled single masked clinical trial to test the clinical efficacy of LightMasks at preventing dark adaptation in the treatment of early diabetic macular oedema (CLEOPATRA)	09/01/2015	25/03/2015							Y						Research Nurse retired and there has been a delay in recruiting a replacement which has caused delays with recruitment. Missed 70 deadline by 5 days.	NHS Provider
14/LO/0203	Clinical Efficacy and Mechanistic Evaluation of Aflibercept for Proliferative Diabetic Retinopathy: A Multicentre Phase IIIb	08/01/2015	10/06/2015							Y						Research Nurse retired and there has been a delay in recruiting a replacement which has caused delays with recruitment	NHS Provider
12/NW/0361	A pragmatic randomised controlled trial comparing the effectiveness and cost effectiveness of levetiracetam and zonisamide versus standard treatments for epilepsy: a comparison of Standard And New Antiepileptic Drugs (SANAD-II)	19/01/2015	03/03/2015													70 day target met	Neither
14/LO/1443	A Phase 3, Randomized, Open-Label, Active-Controlled Study to Evaluate the Efficacy and Safety of Roxatustat in the Maintenance Treatment of Anemia in End Stage Renal Disease Subjects on Stable Dialysis	19/01/2015	NA				Y									15 patients approached but all declined. One patient consented 4/3/15, but within days of randomisation the Sponsor said they were not included because they could not get hold of the required dose of the drug. Still no patients recruited as at 30.9.15	Sponsor
09/H0709/56	Plasma Exchange and Glucocorticoid Dosing in the Treatment of Anti-neutrophil Cyttoplasm Antibody Associated Vasculitis: an international Randomised Controlled Trial	13/01/2015	26/01/2015													70 day target met	Neither

13/LQ/1207	StereoTactic radiotherapy for wet Age-Related macular degeneration (STAR): A randomised, double-masked, sham-controlled, clinical trial comparing low-voltage X-ray irradiation with as needed bevacizumab, to as needed bevacizumab monotherapy.	27/07/2015	07/10/2015											Sponsor delays mean site wasn't activated until 21 September 2015. First available clinic capacity was 07/10/15. 70-day target missed by 2 days.	Sponsor
14/NW/1531	Comparative Testing of 3 mL TransFlow/EDTA Vacuum Blood Collection Tubes (TVTs) and Cyto-Chex 5 mL Blood Collection Tubes (BCTs) Part 1: Equivalence Study.	06/08/2015	24/08/2015											70 day target met	Neither
13/EE/0335	COOL-AMI EU CASE SERIES CLINICAL STUDY: a single-centre case series clinical study to assess the feasibility of integrating therapeutic hypothermia (TH) using the ZOLL IVTM System as an adjunct therapy in percutaneous coronary intervention (PCI) in patients with acute myocardial infarction (AMI).	26/08/2015	N/A											Still within target timeframe	Neither
14/WM/0057	Multi-centre randomised controlled trial to compare the clinical and cost-effectiveness of a vein bypass first* with a best endovascular first revascularisation strategy for severe limb ischemia due to infra-popliteal arterial disease: Bypass vs. Angioplasty in Severe Ischemia of the Leg.	19/08/2015	N/A											Still within target timeframe	Neither
15/SC/0280	Randomised Evaluation of dabigatran esterase Compared to warfarin in pulmonary vein ablation: assessment of an uninterrupted periprocedural anticoagulation strategy (The RE-CIRCUIT Trial)	25/08/2015	N/A											Still within target timeframe	Neither
15/LO/0963	Assessing the reliability and validity of using ultrasound scanning to determine muscle morphology and geometry of the lumbar spine	26/08/2015	N/A											Still within target timeframe	Neither
13/EM/0459	POSNOG – Positive Sentinel Node: adjuvant therapy alone versus adjuvant therapy plus Clearance or axillary radiotherapy. A randomised controlled trial of axillary treatments in women with early stage breast cancer who have metastases in one or two sentinel nodes.	31/08/2015	N/A											Still within target timeframe	Neither
14/SC/1030	A randomised controlled trial to compare the clinical effectiveness and safety of gemtation and ceftriaxone in the treatment of gonorrhoea.	14/09/2015	N/A											Still within target timeframe	Neither
15/LO/0881	A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A One Daily Versus ATRILTA Once-Daily in Treatment Naive HIV - 1 Infected Subjects	28/09/2015	N/A											Still within target timeframe	Neither
15/NW/0505	A Phase III Multicenter, Open-Label, Randomized Study to Evaluate a Switch to MK-1439A in HIV-1-infected Subjects Virologically Suppressed on a Regimen of a Ritonavir-boosted Protease Inhibitor and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs)	28/09/2015	N/A											Still within target timeframe	Neither